
Carmen Argmann, PhD
About Me
Dr. Argmann has a doctorate from the faculty of Science at the University of Western Ontario, Canada where she showed that PPARγ and LXR activation could dramatically reduce macrophage foam cell formation, a key event in atherosclerosis. During her postdoctoral studies at the Institut de Génétique et de Biologie Moléculaire et Cellulaire in Strasbourg, France she contributed to the development of high-throughput mouse metabolic phenotyping protocols and demonstrated that resveratrol, a compound found in red wine, improves mitochondrial function and protects against metabolic disease in vivo.
As a research scientist in Dr Schadt’s genetics group at Rosetta Inpharmatics she contributed to the designing of large-scale genetic mouse crosses to address novel facets of metabolic disease. She was involved in integrating DNA variation, gene expression, and clinical data collected, in order to uncover core networks associated with metabolic disease processes, which in turn were used to identify novel therapeutic targets for the Diabetes and Obesity franchise.
In 2010, during her time in Dr. Aerts’s lab at the Academic Medical Center of the University of Amsterdam, she developed further into an integrative biologist. Her main focus has become applying novel integrative systems biology approaches to understand the hallmarks and key drivers of various human diseases.
Since 2013, she has been an assistant professor at Mount Sinai in the Department of Genetics and Genomic Sciences and is actively applying her integrative biology approaches in various large scale collaborations associated with: generating network models in inflammatory bowel disease; finding novel human beta cell regeneration strategies for Type 2 Diabetes and uncovering genetic modifiers of screenable inborn errors of metabolism. She is also a faculty member of the Icahn Genomics Institute.
Figure: Example schema of the integrative approaches applied to understanding disease processes.
Currently we have one postdoctoral position available. Please contact me at carmen.argmann@mssm.edu
Language
English
Position
ASSOCIATE CLINICAL PROFESSOR | Genetics and Genomic Sciences
Multi-Disciplinary Training Areas
Genetics and Genomic Sciences [GGS]
Video
Education
PhD, University of Western Ontario
Research
Background: Inborn errors of metabolism (IEM) are increasingly viewed as complex diseases as they often present as a spectrum of disease phenotypes with a clear disconnect between the severity of mutation at the primary affected locus and the phenotype. The lack of genotype and phenotype correlation greatly impacts the ability to predict a patient’s disease course. It also illustrates the existence of a fundamental gap in our knowledge of disease pathophysiology. The era of one-gene one-disease is being abandoned, and the contribution of modifying factors considered. However, identifying the modifying factors is not trivial, as rare diseases have rare data.
Hypothesis: We hypothesize that by embracing the concept of IEM as complex diseases that 1. datasets and 2. network approaches generated in populations with common disorders can be used to study disease modifying biology in IEM thereby overcoming the rare disease rare data drawback. Our strategy is based on observing that differentially expressed genes from IEM experimental models highlight highly connected subnetworks in the molecular networks established in common disease populations.
Aim: Our lab’s aim is to use our innovative data-driven multi-scale computational approach to derive and then wet-lab validate novel candidate modifying genes and their associated biology related to the screenable inborn errors of fatty acid oxidation (FAO) the lysosomal storage disorder, Gaucher disease (GD). This is a key collaboration between myself and a faculty expert in IEM, Dr Sander Houten, also of the Department of Genetics and Genomics Sciences at ICAHN.
Impact: Combined these two aims will break new ground for FAO and GD and rare diseases in general by overcoming inherent limitations of rare data through combining novel methodologies with existing data. We furthermore perform validations and these methods which could point the IEM research field into multiple new directions. These novel insights are needed to propel the IEM field into the next generation of understanding.
Publications
Selected Publications
- A Collection of Patient-Derived Intestinal Organoid Lines Reveals Epithelial Phenotypes Associated with Genetic Drivers of Pediatric Inflammatory Bowel Disease. Zahra Shojaei Jeshvaghani, Carmen Argmann, Maaike H. De Vries, Johan H. Van Es, Lauren V. Collen, Daniel Kotlarz, Mia Sveen, Phillip H. Comella, Scott B. Snapper, Christoph Klein, Eric E. Schadt, Hans Clevers, Michal Mokry, Ewart Kuijk, Edward Nieuwenhuis. Inflammatory Bowel Diseases
- Mild Crohn's Disease Is Associated With Altered Sphingolipid Metabolism and Reduced Neutrophilic Inflammation. Arno R. Bourgonje, Susanne Ibing, Palak Rajauria, Jellyana Peraza, Ashwin N. Ananthakrishnan, Carmen Argmann, Marla C. Dubinsky, Henrik A. Jacobsen, Tine Jess, Lone Larsen, Bernhard Y. Renard, Bruce E. Sands, Samir A. Shah, Jason M. Shapiro, Mayte Suarez-Fariñas, Jean Frédéric Colombel, Ryan C. Ungaro. Gastroenterology
- Disease duration impacts intestinal gene expression profiles in Crohn's disease but not in ulcerative colitis. Susanne Ibing, Christopher Tastad, Bernhard Y. Renard, Louis J. Cohen, Carmen Argmann, Drew Helmus, Eric E. Schadt, Miriam Merad, Anjli Kukreja, Sudha Visvanathan, Bruce E. Sands, Marla Dubinsky, Mayte Suarez-Fariñas, Jean Frédéric Colombel, Erwin P. Böttinger, Judy H. Cho, Francesca Petralia, Ryan C. Ungaro. Journal of Crohn's and Colitis